Pleural Mesothelioma Clinical Trial
Official title:
A Phase II, Prospective, Single Arm Trial of Cadonilimab in Combination With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab in combination with bevacizumab and standard chemotherapy as first Line therapy in unresectable pleural mesothelioma.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04914897 -
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
|
Phase 2 | |
Recruiting |
NCT05910112 -
Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention
|
||
Recruiting |
NCT02588131 -
A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)
|
Phase 2 | |
Recruiting |
NCT06362369 -
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
|
Phase 1/Phase 2 | |
Completed |
NCT02414945 -
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT05714553 -
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Completed |
NCT02585362 -
Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program
|
N/A | |
Completed |
NCT00299962 -
Gene Therapy for Pleural Malignancies
|
Phase 1 | |
Terminated |
NCT04106973 -
Mesothelioma Early Detection by VOCs
|
||
Not yet recruiting |
NCT06155279 -
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
|
Phase 2 | |
Not yet recruiting |
NCT06416930 -
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT01160458 -
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
|
Phase 2 | |
Completed |
NCT02899195 -
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
|
Phase 2 | |
Active, not recruiting |
NCT04040231 -
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
|
Phase 1 | |
Completed |
NCT04324437 -
eRAPID: Online Symptom Reporting in Lung Cancer
|
N/A | |
Completed |
NCT04430842 -
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
|
Phase 1 | |
Recruiting |
NCT03210298 -
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
|
||
Terminated |
NCT00895648 -
Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
|
Phase 2 | |
Completed |
NCT00165516 -
Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate
|
Phase 2 |